The post DexCom (DXCM) eyes deeper correction toward $44.11–$20.95 zone appeared on BitcoinEthereumNews.com. DexCom Inc., (DXCM) is a medical device company, that focuses on the design, development & commercialization of glucose monitoring systems globally. It comes under Healthcare sector & trades as “DXCM” ticker at Nasdaq. The DXCM favors double correction in weekly from November-2021 high discussed in last article few months ago. It favors weakness started from 2.17.2025 high & expect downside into $44.11 or lower. DXCM – Elliott Wave latest weekly view In weekly, it ended ((I)) impulse at $164.86 high in November-2021 & now correcting in ((II)). Within ((I)), it ended (I) at $25.82 high in September-2015 & (II) at $10.65 low in September-2017. Above there, it placed (III) as extended move at $114.06 high, (IV) at $76.41 low & finally ended (V) at $164.86 high as ((I)). Below November-2021 high, it favors downside in 7 swings pullback & expect short term bounce in 3, 7 or 11 swings to fail below 7.28.2025 high. DXCM – Elliott Wave view from 3.31.2025 Within ((II)) pullback, it ended (w) at $66.89 low in May-2022 & (x) connector at $142 high in March-2024. Both the moves are 3 swings. It already showing lower low sequence in ((II)) correction, favoring (y) down. Below (x) high, it ended w at $62.34 low, x at $93.25 high & favor downside in y leg. The y is further subdivided in ((A)) ended at $57.52 low, ((B)) at $89.98 high & favoring downside in ((c)) of y of (y). It expects weakness against July-2025 high to extend downside in to $44.11 – $20.95 area or even lower. The sellers can enter the set up in 3, 7 or 11 swings corrective bounce at extreme area for targeting weekly extreme area. Source: https://www.fxstreet.com/news/dexcom-dxcm-eyes-deeper-correction-toward-4411-2095-zone-202511181501The post DexCom (DXCM) eyes deeper correction toward $44.11–$20.95 zone appeared on BitcoinEthereumNews.com. DexCom Inc., (DXCM) is a medical device company, that focuses on the design, development & commercialization of glucose monitoring systems globally. It comes under Healthcare sector & trades as “DXCM” ticker at Nasdaq. The DXCM favors double correction in weekly from November-2021 high discussed in last article few months ago. It favors weakness started from 2.17.2025 high & expect downside into $44.11 or lower. DXCM – Elliott Wave latest weekly view In weekly, it ended ((I)) impulse at $164.86 high in November-2021 & now correcting in ((II)). Within ((I)), it ended (I) at $25.82 high in September-2015 & (II) at $10.65 low in September-2017. Above there, it placed (III) as extended move at $114.06 high, (IV) at $76.41 low & finally ended (V) at $164.86 high as ((I)). Below November-2021 high, it favors downside in 7 swings pullback & expect short term bounce in 3, 7 or 11 swings to fail below 7.28.2025 high. DXCM – Elliott Wave view from 3.31.2025 Within ((II)) pullback, it ended (w) at $66.89 low in May-2022 & (x) connector at $142 high in March-2024. Both the moves are 3 swings. It already showing lower low sequence in ((II)) correction, favoring (y) down. Below (x) high, it ended w at $62.34 low, x at $93.25 high & favor downside in y leg. The y is further subdivided in ((A)) ended at $57.52 low, ((B)) at $89.98 high & favoring downside in ((c)) of y of (y). It expects weakness against July-2025 high to extend downside in to $44.11 – $20.95 area or even lower. The sellers can enter the set up in 3, 7 or 11 swings corrective bounce at extreme area for targeting weekly extreme area. Source: https://www.fxstreet.com/news/dexcom-dxcm-eyes-deeper-correction-toward-4411-2095-zone-202511181501

DexCom (DXCM) eyes deeper correction toward $44.11–$20.95 zone

DexCom Inc., (DXCM) is a medical device company, that focuses on the design, development & commercialization of glucose monitoring systems globally. It comes under Healthcare sector & trades as “DXCM” ticker at Nasdaq.

The DXCM favors double correction in weekly from November-2021 high discussed in last article few months ago. It favors weakness started from 2.17.2025 high & expect downside into $44.11 or lower.

DXCM – Elliott Wave latest weekly view

In weekly, it ended ((I)) impulse at $164.86 high in November-2021 & now correcting in ((II)). Within ((I)), it ended (I) at $25.82 high in September-2015 & (II) at $10.65 low in September-2017. Above there, it placed (III) as extended move at $114.06 high, (IV) at $76.41 low & finally ended (V) at $164.86 high as ((I)). Below November-2021 high, it favors downside in 7 swings pullback & expect short term bounce in 3, 7 or 11 swings to fail below 7.28.2025 high.

DXCM – Elliott Wave view from 3.31.2025

Within ((II)) pullback, it ended (w) at $66.89 low in May-2022 & (x) connector at $142 high in March-2024. Both the moves are 3 swings. It already showing lower low sequence in ((II)) correction, favoring (y) down. Below (x) high, it ended w at $62.34 low, x at $93.25 high & favor downside in y leg. The y is further subdivided in ((A)) ended at $57.52 low, ((B)) at $89.98 high & favoring downside in ((c)) of y of (y). It expects weakness against July-2025 high to extend downside in to $44.11 – $20.95 area or even lower. The sellers can enter the set up in 3, 7 or 11 swings corrective bounce at extreme area for targeting weekly extreme area.

Source: https://www.fxstreet.com/news/dexcom-dxcm-eyes-deeper-correction-toward-4411-2095-zone-202511181501

Market Opportunity
WorldAssets Logo
WorldAssets Price(INC)
$1.1186
$1.1186$1.1186
+7.05%
USD
WorldAssets (INC) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.